PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Mattia D'Agostino, 386633

EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS

EHA Library, David Zihala, 386634

TRACKING THE CLONAL EVOLUTION AND DRUG RESISTANCE PATHWAY OF NEWLY DIAGNOSED MULTIPLE MYELOMA THROUGH SINGLE-CELL RNA SEQUENCING

EHA Library, Jian Cui, 386635

CLASS Ⅱ FERROPTOSIS INDUCERS ARE A NOVEL THERAPEUTIC APPROACH FOR T(4;14)-POSITIVE MULTIPLE MYELOMA

EHA Library, Chunyan Sun, 386636

CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS

EHA Library, Sabrina Prommersberger, 386637

A NOVEL INDIRUBIN-3-MONOXIME DERIVATIVES FUNCTION AS DISRUPTORS OF PROTEOSTASIS VIA TARGETING TRIM28 IN MULTIPLE MYELOMA

EHA Library, Teng Fang, 386639

PIM2 KINASE REGULATES TIGIT EXPRESSION AND ENERGY METABOLISM IN NK CELLS OF PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 386640

PREDICTING HIGH-RISK DISEASE BIOLOGY USING ARTIFICIAL INTELLIGENCE BASED FDG PET/CT RADIOMICS IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Jacob Shreve, 386641

MALIGNANT PLASMA CELLS PROMOTE EXPANSION OF REGULATORY T CELLS TO CREATE A PROTECTIVE “IMMUNE SHIELD”

EHA Library, Roberto Limongello, 386642

ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA

EHA Library, Marietta Truger, 386643

HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING

EHA Library, Kevin C. Hart, 386644

PHARMACODYNAMIC ACTIVITY OF GEN3014 (HEXABODY-CD38) IN PATIENTS WITH MULTIPLE MYELOMA SUPPORTS ENHANCED COMPLEMENT DEPENDENT CYTOTOXICITY OF GEN3014 COMPARED TO DARATUMUMAB

EHA Library, Ida H. Hiemstra, 386645

VALIDATION OF THE SECOND REVISED INTERNATIONAL STAGING SYSTEM (R2-ISS) IN A LARGE POPULATION-BASED, NATIONWIDE COHORT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Christian Brieghel, 386646

DNP73 PROMOTES DRUG RESISTANCE AND IMMUNE EVASION IN MULTIPLE MYELOMA BY MODULATING MYC/CD47 AXIS

EHA Library, Lanting Liu, 386647

CONTRIBUTION OF IMMUNOPHENOTYPING OF BONE MARROW B CELLS AND PLASMA CELLS IN THE DIAGNOSTIC CLASSIFICATION OF INDIVIDUALS PRESENTING WITH A SERUM M-PROTEIN

EHA Library, Juan Flores-Montero, 386648

POTENTIAL IMMUNOSUPPRESSIVE EFFECT OF EXTRACELLULAR VESICLES FROM PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Shinya Hagiwara, 386649

HIGH-DIMENSIONAL SPECTRAL CYTOMETRY CHARACTERIZATION OF THE CIRCULATING IMMUNE CELL PROFILE IN ASYMPTOMATIC AND SYMPTOMATIC MYELOMA PATIENTS.

EHA Library, Joana Caetano, 386650

EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES

EHA Library, Laura Martinez-Verbo, 386651

BONE MARROW-FREE SEQUENCING OF M PROTEIN GENES IN MONOCLONAL GAMMOPATHIES

EHA Library, Mario Nuvolone, 386652

LNCRNA SNHG15 BINDS DDX5 TO INDUCE R-LOOP-BASED DNA DAMAGE REPAIR TO PROMOTE BTZ RESISTANCE IN MULTIPLE MYELOMA

EHA Library, Qiuling Wu, 386653

SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS) WITH IV VS SUBCUTANEOUS (SC) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Luciano Costa, 386654

THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING

EHA Library, Maria Papatsirou, 386655

STUDY ON THE PERCENTAGE AND FUNCTION OF TSCM CELLS AND THE ANTITUMOR EFFECT IN VITRO AMPLIFICATION IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Panpan Cao, 386656

EFFECT OF ANTI-CD38 MONOCLONAL ANTIBODIES ON THE INTERACTION OF MYELOMA CELLS WITH BONE MARROW STROMAL CELLS

EHA Library, Olga Blau, 386657

GENOMIC PROFILING IN CFDNA COMPLEMENTS MOLECULAR DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Anke Schilhabel, 386658

IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA

EHA Library, Nicolas Thomas Iannozzi, 386659

NOVEL IMMUNOSUPPRESSIVE MYELOID POPULATIONS IN THE BONE MARROW (BM) AND OSTEOLYTIC LESIONS (OL) OF MULTIPLE MYELOMA (MM) PATIENTS

EHA Library, Jens Hillengass, 386660

PROSPECTIVE REAL-WORLD EVALUATION OF THE PREVALENCE OF T(11;14) IN MULTIPLE MYELOMA: THIRD INTERIM ANALYSIS FROM THE MEDICI STUDY

EHA Library, Maria Gavriatopoulou, 386661

MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA

EHA Library, Hamed Bashiri, 386662

MULTIPARAMETRIC FLOW CYTOMETRY FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH IGM MONOCLONAL GAMMOPATHIES

EHA Library, Tina Bagratuni, 386663

IN SILICO PREDICTION REVEALS PUTATIVE T-CELL CLASS I/II NEOEPITOPES WITHIN THE CLONOTYPIC IMMUNOGLOBULIN HEAVY AND LIGHT CHAINS IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Glykeria Gkoliou, 386664

ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA

EHA Library, Anna Bielowski, 386665

MULTIPLE MYELOMA AND ADJACENT NK CELLS CAN EXPRESS THE MACHINERY TO INTEGRATE NEURONAL SIGNALS

EHA Library, Ana Filipa Barahona, 386666

EXOSOME MIRNAS PROFILING IN SERUM AND PROGNOSTIC EVALUATION IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Teng Fang, 386667

GAIN OF CHROMOSOME 1Q LEADS TO HIGH EXPRESSION OF SNORD78 AND ABERRANT RIBOSOME METHYLATION

EHA Library, Duoduo Zhao, 386668

ASSESSMENT OF CONVENTIONAL TRANSLOCATIONS AND IG REARRANGEMENTS IN THE DIAGNOSIS OF MULTIPLE MYELOMA PATIENTS USING A TARGETED CAPTURE-HYBRIDIZATION RNA SEQUENCING PANEL.

EHA Library, Natalia Buenache Cuenda, 386669

MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY

EHA Library, Ana Bela Sarmento-Ribeiro, 386670

RAS-ERK PATHWAY GENES MUTATIONS IN THE LESIONS FROM VARIOUS TUMOR LOCI IN MULTIPLE MYELOMA

EHA Library, Maiia Soloveva, 386671

ABERRANT M5C MODIFICATION OF LNCRNA MALAT1 IS ASSOCIATED WITH BONE LESIONS FORMATION IN MULTIPLE MYELOMA

EHA Library, Xing Cui, 386672

GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING

EHA Library, Jian Cui, 386673

DECIPHERING PLASMA CELL HETEROGENEITY AND TRANSCRIPTOME FEATURES IN POEMS SYNDROME USING SINGLE CELL RNA-SEQUENCING

EHA Library, Haiyan He, 386674

GENERATION OF A FIRST-IN-CLASS INHIBITOR FOR THE MASTER ONCOREGULATOR HNRNP K IN HAEMATOLOGICAL MALIGNANCIES

EHA Library, Álvaro Otero-Sobrino, 386675

BIOLOGICAL AND MOLECULAR CHARACTERIZATION OF IN SILICO IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY WITH POTENTIAL ANTI-MULTIPLE MYELOMA ACTIVITY.

EHA Library, Valentina Traini, 386676

EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.

EHA Library, Cristina De Ramón Sánchez, 386677

DEVELOPMENT OF A QUANTITATIVE ASSAY FOR ASSESSING BCL2’S PPI COMPLEXES AND ITS APPLICATION AS A TARGET ENGAGEMENT ASSAY IN CLINICAL SPECIMENS WITH MULTIPLE MYELOMA

EHA Library, Hongwon Lee, 386678

THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA

EHA Library, Alba Rodríguez-García, 386679

ANTIBODY TARGETING OF SOLUBLE MHC-CLASS-I-RELATED MOLECULE AUGMENTS NATURAL KILLER CELL FUNCTION BY RESTORING NKG2D IN MULTIPLE MYELOMA

EHA Library, Hyunsoo Cho, 386680

ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMA CELLS

EHA Library, Alessandra Romano, 386681

AUTOMATED SEPARATION OF CELL CLUSTERS PROVIDES AN EASY AND ACCURATE STRATEGY FOR THE ANALYSIS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MIELOMA IN SINGLE 11-COLORS FLOW CYTOMETRY COMBINATION.

EHA Library, Paula Piñero, 386682

EFFECT OF HPSE AND HPSE2 SNPS ON THE RISK OF DEVELOPING PRIMARY PARASKELETAL MULTIPLE MYELOMA

EHA Library, Olga Ostrovsky, 386683

FERROPTOSIS AS A NEW BCMA-TARGETED IMMUNOTHERAPY OFF-TARGET EFFECT IN MULTIPLE MYELOMA

EHA Library, ALESSANDRA ROMANO, 386684

MULTIPLE MYELOMA DERIVED IL-6 REDUCES FATTY ACID METABOLISM IN THE LIVER BY DOWNREGULATING CD36 AND CPT1A IN HEPATOCYTES

EHA Library, Martha Egheose Ehikioya, 386685

COMPARISON OF MULTIPLE MYELOMA TREATMENT PATTERNS IN 2022 ACROSS UNITED STATES, SOUTH AMERICA, EUROPE AND ASIA

EHA Library, Philippe Capart, 386686

FUNCTIONAL STUDIES IN MULTIPLE MYELOMA CELL LINESWITH OVEREXPRESSION OF NRAS Q61R MUTATION

EHA Library, Romano Liotti, 386687

PROGNOSTIC IMPACT OF OPIOID USE PRIOR TO DIAGNOSIS OF MULTIPLE MYELOMA

EHA Library, Christian Brieghel, 386688

CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS

EHA Library, Ilaria Vigliotta, 386689

PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY

EHA Library, Panagiotis Malandrakis, 386690

A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Katja Weisel, 386691

AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Emma Searle, 386692

TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY

EHA Library, Carlyn Tan, 386694

IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY

EHA Library, Salomon Manier, 386695

CT103A, A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF PHASE 1B/2 STUDY (FUMANBA-1)

EHA Library, Chunrui Li, 386696

MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL

EHA Library, Nizar J Bahlis, 386697

UPDATED RESULTS OF A PHASE I, OPEN-LABEL STUDY OF BCMA/CD19 DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Juan Du, 386698

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES

EHA Library, Salomon Manier, 386699

IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C

EHA Library, Melissa Alsina, 386700

EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)

EHA Library, Meral Beksac, 386701

IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: UPDATE OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA

EHA Library, Junling Zhuang, 386702

REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

EHA Library, Frida Bugge Askeland, 386704

ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS

EHA Library, Enrique Maria Ocio San Miguel, 386705

IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

EHA Library, Kaz Groen, 386706

SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY

EHA Library, Paula Rodríguez-Otero, 386707

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3

EHA Library, Xavier Leleu, 386709

POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY

EHA Library, Nizar J Bahlis, 386711

ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY

EHA Library, Sandy W. Wong, 386712

BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY

EHA Library, Evangelos Terpos, 386713

SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES

EHA Library, Charalampos Charalampous, 386714

EFFICACY, SURVIVAL AND SAFETY OF SELINEXOR, BORTEZOMIB AND DEXAMETHASONE (SVD) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SUBGROUP DATA FROM THE BOSTON TRIAL

EHA Library, María-Victoria Mateos, 386715

PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

EHA Library, Luis-Esteban Tamariz-Amador, 386716

MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Ajai Chari, 386717

POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA

EHA Library, Hila Magen, 386718

COMBINING SKY92 GENE EXPRESSION PROFILING WITH CYTOGENETICS ACCORDING TO R2-ISS FOR MULTIPLE MYELOMA RISK CLASSIFICATION: THE FIRST PROSPECTIVE EVIDENCE

EHA Library, Xiang Zhou, 386719

IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).

EHA Library, Margaret Macro, 386720

COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS

EHA Library, Albert Oriol, 386722

INFECTION RISK BEFORE DIAGNOSIS OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: RESULTS FROM THE SCREENED POPULATION-BASED ISTOPMM STUDY

EHA Library, Marina Ros Levy, 386723

DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL

EHA Library, Vittorio Montefusco, 386724

VALUE OF 18F-FDG PET/CT IN THE EVALUATION OF ORGAN INVOLVEMENT IN NEWLY DIAGNOSED PRIMARY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

EHA Library, Junru Liu, 386725

EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI-MYELOMA TREATMENTS ON POST- PROGRESSION OUTCOMES IN THE REAL-WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE.

EHA Library, Eirini Katodritou, 386726

A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

EHA Library, Raija Silvennoinen, 386727

HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS

EHA Library, Monique Minnema, 386728

INVOLVED/UNINVOLVED SERUM FREE LIGHT CHAIN RATIO IS A STRONGER PREDICTOR OF DIAGNOSTIC/RISK FACTORS IN LIGHT CHAIN COMPARED TO HEAVY CHAIN MONOCLONAL GAMMOPATHIES

EHA Library, Jon Thorir Oskarsson, 386729

DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY

EHA Library, Evangelos Terpos, 386730

ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.

EHA Library, David H. Vesole, 386731

CLINICAL UTILITY OF MONOCLONAL GAMMOPATHY SCREENING IN THE EVALUATION OF PERIPHERAL NEUROPATHY

EHA Library, Mackenzie Maberry, 386732

MATERNAL AND FETAL OUTCOMES IN PREGNANCIES OF WOMEN WITH IMMUNE THROMBOCYTOPENIA: A MULTICENTER RETROSPECTIVE OBSERVATIONAL ITP-NET  ITALIAN STUDY

EHA Library, Monica Carpenedo, 387998

ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY

EHA Library, Ming Hou, 387999

ASSESSMENT OF JOINT HEALTH IN PATIENTS RECEIVING PROPHYLAXIS FOR HAEMOPHILIA A IN FIVE EUROPEAN COUNTRIES: A CROSS-SECTIONAL SURVEY

EHA Library, Hortensia De la Corte-Rodríguez, 388000

CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX

EHA Library, Beatrice Nolan, 388001

LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY

EHA Library, Monica Carpenedo, 388002

A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS

EHA Library, Guy Young, 388003